Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model

Anti-Cancer Drugs

Volumn 21, Issue 9, 2010, Pages 861-867

  Dean, Nichole Renae ^a   Knowles, Joseph A ^a   Helman, Emily E ^a   Aldridge, Joszi C ^a   Carroll, William R ^a   Magnuson, Jeffery Scott ^a   Clemons, Lisa ^a   Ziober, Barry ^b   Rosenthal, Eben L ^a  

^a University of Alabama at Birmingham   (United States)

^b Centocor ^*  (United States)

Author keywords

anti EMMPRIN antibody; CNTO3899; ex vivo; head and neck squamous cell carcinoma; tissue slices

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ACTIN; CASPASE 3; CASPASE 8; CD147 ANTIGEN; CETUXIMAB; CNTO 3899; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MODEL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEASIBILITY STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956412011     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833d1a11     Document Type: Article

References (26)

1. Jemal A, Siegel R,Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001; 132 (Suppl):7S-11S.
3. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115:922-935.
4. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002; 12:11-20.
5. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
6. Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R, Gladson CL. Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 2003; 113:1406-1410.
7. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55:434-439.
8. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006; 119:1800-1810.
9. Bordador LC, Li X, Toole B, Chen B, Regezi J, Zardi L, et al. Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 2000; 85:347-352.
10. Schlegel J, Redzic JS, Porter CC, Yurchenko V, Bukrinsky M, LabeikovskyW, et al. Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol 2009; 391:518-535.
11. Rosenthal EL, Zhang W, Talbert M, Raisch KP, Peters GE. Extracellular matrix metalloprotease inducer-expressing head and neck squamous cell carcinoma cells promote fibroblast-mediated type I collagen degradation in vitro. Mol Cancer Res 2005; 3:195-202.
12. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 2001; 158:1921-1928.
13. Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblastderived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006; 6:52.
14. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002; 19:697-702.
15. Newman JR, Bohannon IA, ZhangW, Skipper JB, GrizzleWE, Rosenthal EL. Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer. Arch Otolaryngol Head Neck Surg 2008; 134:1218-1224.
16. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65:3193-3199.
17. Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, et al. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 2009; 15:4058-4065.
18. Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007; 105:291-298.
19. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243.
20. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004; 10:8697-8703.
21. Kendrick JE, Straughn JM Jr, Oliver PG,Wang W, Nan L, Grizzle WE, et al. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol 2008; 108:591-597.
22. Baba M, Inoue M, Itoh K, Nishizawa Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun 2008; 374:111-116.
23. Newman JR, Helman EE, Safavy S, Zhang W, Rosenthal EL. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett 2009; 274:313-318.
24. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25:4798-4811.
25. Ju XZ, Yang JM, Zhou XY, Li ZT, Wu XH. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res 2008; 14:494-501.
26. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13:4407-4414.